In vitro effect of DNA topoisomerase inhibitors on Candida albicans

Medical Mycology

Volumn 48, Issue 1, 2010, Pages 155-160

  Kwok, Shing C ^a   Schelenz, Silke ^b   Wang, Xia ^a   Steverding, Dietmar ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antifungal activities; Candida albicans; DNA topoisomerase inhibitors

Indexed keywords

ACLARUBICIN; BETA LAPACHONE; CAMPTOTHECIN; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; IDARUBICIN; IRINOTECAN; MITOXANTRONE; TOPOTECAN; ANTIFUNGAL AGENT; ENZYME INHIBITOR; FUNGAL PROTEIN;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; FUNGAL MORPHOLOGY; FUNGUS GROWTH; FUNGUS HYPHAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; MICROSCOPY; YEAST;

CANDIDA ALBICANS; FUNGI;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; ENZYME INHIBITORS; FUNGAL PROTEINS; HUMANS; HYPHAE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY; TOPOISOMERASE I INHIBITORS; YEASTS;

EID: 74949125329     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903114934     Document Type: Article

References (27)

1. Deacon JW. Fungal Biology. Oxford: Blackwell Publishing, 2005.
2. Mavor AL, Thewes S, Hube B. Systemic fungal infections caused by Candida species: epidemiology, infection process and virulence attributes. Curr Drug Targets 2005; 6: 863-874.
3. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007; 45: 305-320.
4. R ichardson MD Changing patterns and trends in systemic fungal infections. J Antimicrobial Chemother 2005; 56 (Suppl. 1): i5-i11.
5. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 61-189.
6. White TC, Marr KA, Bowden RA. Clinical, cellular and molecular factors that contribute to antifungal resistance. Clin Microbiol Rev. 1998; 12: 382-402.
7. Snydman DR. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 2003; 123 (5 Supp0): 500S-503S.
8. Nucci M, Perfect JR. When antifungal therapy fails. Clin Infect Dis 2008; 46: 1426-1433.
9. Klepser ME. Antifungal resistance among Candida species. Pharmacotherapy 2001; 21: 124S-132S.
10. Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother. 1998; 42: 2645-2649.
11. Cowen LE, Steinbach WJ. Stress, drugs and evolution: the role of cellular signalling in fungal drug resistance. Eukaryot Cell 2008; 7: 747-764.
12. Cannon RD, Lamping E, Holmes AR, et al. Candida albicans drug resistance-another way to cope with stress. Microbiology 2007; 153: 3211-3217.
13. Rodríguez-Tudela JL, Barchiesi F, Bille J, et al. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin Microbiol Infect 2003 ; 9 : i-viii.
14. Huber W, Koella JC. A comparison of three methods of estimating EC 50 in studies of drug resistance of malaria parasites. Acta Trop 1993; 55: 257-261.
15. Hughes CE, Beggs WH. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother 1987; 19: 171-174.
16. Corbett KD, Berger JM. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 2004; 33: 95-118.
17. Bates AD, Maxwell A. D NA Topology. Oxford: Oxford University Press; 2005.
18. Fostel JM, Montgomery DA, Shen LL. Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery. Antimicrob Agents Chemother 1992; 36: 2131-2138.
19. Shen LL, Baranowski J, Fostel J, Montgomery DA, Lartey PA. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob Agents Chemother 1992; 36: 2778-2784.
20. Kim BS, Moon SS, Hwang BK. Structure elucidation and antifungal activity of an anthracycline antibiotic, daunomycin, isolated from Actinomadura roseola. J Agric Food Chem 2000; 48: 1875-1881.
21. Bridewell DJ, Finlay GJ, Baguley BC. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I. Oncol Res 1997; 9: 535-542.
22. Figueiredo-Pereira ME, Chen WE, Li J, Johdo O. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 Sproteasome. J Biol Chem 1996; 271: 16455-16459.
23. Cutler JE. Putative virulence factors of Candida albicans. A nnu Rev Microbiol 1991; 45: 187-218.
24. Lo HJ, Köhler JR, DiDomenico B, et al. Nonfi lamentous C. albicans mutants are avirulent. Cell 1997; 90: 939-949.
25. Shepherd MG, Yin CY, Ram SP, Sullivan PA. Germ tube induction in Candida albicans. Can J Microbiol 1980; 26: 21-26.
26. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. London : Pharmaceutical Press, 2002.
27. Dorr RT, Bozak KA, Shipp NG, et al. In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/ protein ratios. Cancer Res 1988; 48: 5222-5227.